First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2014-07-25 06:12:48Open Document File Size: 3,25 MBShare Result on FacebookCityMadrid / Berlin / Graz / /CompanyLG / Martin Lange1 Bayer Pharma AG / Lilly / EPO / Bayer HealthCare Pharmaceuticals / CSC / /ContinentEurope / /CountryGermany / Austria / Spain / /FacilityPlanck Institute / Medical University of Graz / Comprehensive Cancer Center / Institute of Pathology / /IndustryTermTreatment of patient-derived cancer / /MedicalConditioncolon tumors / tumor / common cancer / cancer / tumors / disease / strain / colon cancers / variable tumor / patient-derived colon cancer / colon cancer / M BB Colon cancer / BB Patient-derived cancer / cancer stem cells / patient-derived cancer / Patient-derived colon cancers / cell strain BB Patient-derived cancer / therapy-resistant cancer / BB Tumor / patient-derived colon tumors / BB Patient-derived colon cancer / /OrganizationInstitute of Pathology / Medical University of Graz / 6Max Planck Institute for Molecular Genetics / European Union / Comprehensive Cancer Center / /PersonJoseph L Regan / Rachel Fairbanks / / /PositionApoptosis EP HB / /ProgrammingLanguageRC / /TechnologyGene expression / stem cells / Apoptosis / /URLwww.OncoTrack.eu / /SocialTag |